Last updated: May 25, 2026
Budesonide/Formoterol Fumarate Dihydrate Suppliers: Who Makes the API, Fixed-Dose Combination, and Key Components?
Budesonide/formoterol fumarate dihydrate (inhaled fixed-dose combination, ICS/LABA) is typically supplied through a split model: (1) active pharmaceutical ingredient (API) manufacturers for budesonide and formoterol fumarate dihydrate and (2) formulation and device-directional partners for marketed inhalers (pressurized metered-dose inhalers and dry powder inhalers). Supplier lists below focus on companies that are known to produce one or both APIs and/or commercially supply inhaled budesonide/formoterol products, based on documented industry manufacturing footprints and regulatory submissions tied to these substances.
What companies supply budesonide API for inhaled combination products?
Budesonide API manufacturers (typical global sources)
Key supplier categories for budesonide API include large scale chemical producers and specialty inhalation/API houses.
Commonly used budesonide API supply channels include:
- Standalone budesonide API producers supplying global generic and branded formulation sites.
- Contract manufacturing organizations (CMOs) that compound budesonide into inhalation-grade bulk and finished intermediates.
- In-house vertical supply from companies marketing combination products.
How budesonide API supply impacts combination availability
For budesonide/formoterol combinations, bottlenecks usually map to:
- supply of inhalation-grade micronized/suspended budesonide or particle engineered solids (for DPI),
- quality system readiness for combination-device filling,
- control strategy for polymorphs and impurity profiles tied to budesonide.
What companies supply formoterol fumarate dihydrate API for inhaled combination products?
Formoterol fumarate dihydrate API manufacturers
Formoterol fumarate dihydrate has fewer but highly specialized commercial suppliers versus many small molecules. The market usually relies on:
- API producers with established heteroaromatic synthesis capability and salt-form control,
- inhalation-focused suppliers who manage residual solvents, crystal habit, and water content for dihydrate consistency,
- CMOs and formulation sites that standardize particle size distributions for inhalation performance.
Salt form and dihydrate control
Because the target is “formoterol fumarate dihydrate,” supplier qualification often hinges on:
- confirming dihydrate content (loss on drying range and water activity),
- consistent fumarate counterion impurity sets,
- downstream suitability for either suspension MDI fill or DPI blend.
Which suppliers provide the finished budesonide/formoterol combination inhalers?
Branded originators and major commercial product suppliers
Marketed budesonide/formoterol products are sold by multiple brand holders across geographies, with manufacturing distributed among:
- the brand holder’s sites,
- licensed manufacturing by specialty inhalation manufacturers,
- device-filling and packaging contractors.
MDI vs DPI: supplier structures differ
- Pressurized metered-dose inhalers (pMDIs): require propellant systems, stainless/aluminum canister sourcing, valve and actuator supply, and filling line capacity.
- Dry powder inhalers (DPIs): require micronization and blending of budesonide, and tight control of the dose uniformity and flow properties for formoterol blend systems, plus device-specific dose capsule or reservoir filling.
What device and component suppliers matter for budesonide/formoterol inhalers?
Actuators, valves, canisters, and propellant system suppliers
For combination inhalers, component supply can determine lead times as much as API supply:
- valve and actuator component manufacturers (precision machining and elastomer qualification),
- canister and crimp system suppliers,
- propellant and compatible elastomer suppliers for pMDIs,
- DPI device platform manufacturers (for reservoir, capsule, and airflow management features).
Why component supply affects patent and regulatory filings
Manufacturing changes to:
- canister type,
- valve/actuator configuration,
- inhaler device performance characteristics,
can trigger bridge studies and regulatory comparability requirements. This increases supplier importance beyond pure API cost.
How many suppliers typically exist in the budesonide/formoterol supply chain?
Practical supplier count by supply layer
- Budesonide API: multiple qualified global API suppliers.
- Formoterol fumarate dihydrate API: fewer qualified suppliers than budesonide.
- Fixed-dose formulation and device filling: usually concentrated in a smaller set of inhalation specialists and licensed manufacturers.
- Device components (valves, canisters, actuators, DPI platforms): supplied by a dedicated component ecosystem with long qualification cycles.
What contract manufacturing organizations (CMOs) support budesonide/formoterol combination products?
Covers both formulation and device filling
CMOs that support these programs generally provide:
- inhalation suspension or dry powder blending,
- particle size and aerosol performance development (for DPI),
- can filling and packaging (for pMDI),
- stability testing and release testing aligned to inhalation standards.
Quality systems and inhalation validation
For inhalation products, CMO capability must include:
- validated filling accuracy for low-dose blend systems,
- moisture control for dihydrate APIs,
- cleaning validation for shared lines,
- extractables/leachables control where relevant to canister/valve systems.
Which suppliers compete for US and EU market demand?
US-centric and EU-centric sourcing patterns
- US and EU marketed products tend to pull from multinational inhalation supply networks with pre-qualified facilities for regulatory filings.
- Local supply pressure can shift to contract manufacturing when brand holders optimize cost and inventory.
Commercial implication
Where supplier concentration is high (notably formoterol API and specific inhaler component ecosystems), lead time risk is more material than API lead time alone.
Key Takeaways
- Budesonide/formoterol fumarate dihydrate supply usually splits into budesonide API, formoterol fumarate dihydrate API, and inhalation-device formulation and filling.
- Formoterol dihydrate API supply is typically more concentrated and therefore more sensitive to qualifying new vendors.
- Inhaler component ecosystems (valves, canisters, actuators, DPI platforms) often become the real schedule constraint, especially for pMDIs and device-matched DPIs.
- Supplier qualification is dominated by inhalation-grade quality attributes: particle properties, dihydrate water content, impurity profiles, and dose uniformity performance through the device.
FAQs
1) Who supplies budesonide/formoterol for generic inhaler programs?
Generic inhaler programs typically source budesonide and formoterol APIs from established API producers and rely on inhalation CMOs for formulation and device filling, with vendor selection driven by regulatory comparability and inhalation performance capability.
2) Are budesonide and formoterol dihydrate supplied separately or as a combined intermediate?
They are most often supplied as separate APIs that are blended or formulated together at the inhalation manufacturer/CMO stage. Combined intermediates are less common due to formulation-device matching needs.
3) What is the biggest procurement risk for budesonide/formoterol products?
The biggest procurement risk is usually not just API availability, but supply continuity for inhaler-device components and inhalation-specific manufacturing capacity (filling, packaging, and device performance validation).
4) Can new API suppliers be used without revalidation?
In inhaled combination products, switching API supplier almost always requires comparability work, because particle/dihydrate behavior and impurity profiles can affect aerosol performance and stability.
5) Do supply risks differ between pMDI and DPI versions?
Yes. pMDI versions concentrate risk in can/valve/actuator and propellant system availability. DPI versions concentrate risk in blend uniformity, moisture/flow control, and device capsule or reservoir filling.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Inhalation Drug Products: Current Good Manufacturing Practice (CGMP) for the 21st Century. U.S. Food and Drug Administration.
- EMA. Guideline on the quality of inhalation products. European Medicines Agency.
